RespireRx Pharmaceuticals Inc (fka RSPI)

[haysaw]

Thanks for the insight and stories, Neuro.

You make a case for heightened leverage for BP, in light of the bargains and desperation out there in biotechland. My question is: How much does this matter if/when several interested (BP) parties enter the fray for a novel compound w/out competition (assuming Cor can create that buzz)? Does Cortex have what it takes to stay strong and patient in a room of powerful BP negotiators looking to author the terms of a deal? I hope they can, although I have my doubts.

Also, do they have the ability to seek out an alternative funding plan (absent a good BP partnership or good R&R/JMP financing)? My concern is, that since they have been very conventional/uncreative in this arena in the last several years, we will get more of the same disappointment.

Finally, was Ceph at the Wyndhover Conf?

Thanks in advance.